Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits

The current interest in recombinant factor VIII (rFVIII) products stems from the fact that they offer a technological solution to prolonging the half-life of and reducing the risk of formation of alloantibodies (inhibitors) against FVIII in treated patients with hemophilia A (HA). The Italian health...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiavoni, Mario, Napolitano, Mariasanta, Giuffrida, Gaetano, Coluccia, Antonella, Siragusa, Sergio, Calafiore, Valeria, Lassandro, Giuseppe, Giordano, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901793/
https://www.ncbi.nlm.nih.gov/pubmed/31850352
http://dx.doi.org/10.3389/fmed.2019.00261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901793/
https://www.ncbi.nlm.nih.gov/pubmed/31850352
http://dx.doi.org/10.3389/fmed.2019.00261

Ejemplares similares